OpenArc Corporate Advisory’s Royalty Pharma RPRX Stock Holding History

OpenArc Corporate Advisory’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$279K	Buy	4,974 +213	+4%	+$11.1K	﹤0.01%	649
2026 Q1	$228K	Buy	+4,761	New	+$209K	﹤0.01%	643

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OpenArc Corporate Advisory's RPRX Position: Q2 2026 in Review

OpenArc Corporate Advisory increased its Royalty Pharma (RPRX) stake by 4.5% in Q2 2026, buying an estimated $11.1K and bringing the position to 4,974 shares worth $279K. The position accounts for ﹤0.01% of the portfolio, ranked #649.

OpenArc Corporate Advisory first reported a position in RPRX in Q1 2026 and has held it in 2 quarters since. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

OpenArc Corporate Advisory held 4,974 shares of Royalty Pharma worth $279K as of Q2 2026.
OpenArc Corporate Advisory bought 213 Royalty Pharma shares in Q2 2026, an estimated $11.1K.
Royalty Pharma made up ﹤0.01% of OpenArc Corporate Advisory's portfolio in Q2 2026, its #649 holding.
OpenArc Corporate Advisory first reported a position in Royalty Pharma in Q1 2026 and has held it in 2 quarters since.
641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on OpenArc Corporate Advisory's 13F filing for Q2 2026, filed 5 Aug 2026.